Desmoid Fibromatosis
9
3
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 9 trials
100.0%
+13.4% vs benchmark
11%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (9)
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Observing People With Desmoid-Type Fibromatosis
Electrochemotherapy for Desmoid Tumors
Project: Every Child for Younger Patients With Cancer
Treatment of Desmoid Fibromatosis With Arterial Embolization
A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors
Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis